Dennis Henner Net Worth
The estimated Net Worth of Dennis Henner is at least $73.5 Million dollars as of 2 July 2018. Dennis Henner owns over 200,000 units of Forty Seven stock worth over $30,573,778 and over the last 16 years he sold FTSV stock worth over $42,968,350. In addition, he makes $0 as Independent Director at Forty Seven.
Dennis Henner FTSV stock SEC Form 4 insider trading
Dennis has made over 19 trades of the Forty Seven stock since 2004, according to the Form 4 filled with the SEC. Most recently he bought 200,000 units of FTSV stock worth $3,200,000 on 2 July 2018.
The largest trade he’s ever made was selling 868,055 units of Forty Seven stock on 23 November 2004 worth over $20,390,612. On average, Dennis trades about 101,751 units every 238 days since 2004. As of 2 July 2018 he still owns at least 3,816,951 units of Forty Seven stock.
You can see the complete history of Dennis Henner stock trades at the bottom of the page.
Dennis Henner biography
Dr. Dennis J. Henner is Independent Director of the Company. He is the Chief Scientific Advisor of Clarus Ventures, LLC, a venture capital firm, where he served as Managing Director from the firm’s inception in March 2005 to January 2018. Prior to Clarus, Dr. Henner was a General Partner at MPM Capital, a healthcare venture capital firm. From 1981 to 2001, Dr. Henner was an executive at Genentech, where he held various positions including Senior Vice President of Research, and was a member of Genentech’s executive committee. Dr. Henner previously served as a member of the board of directors of Aerie Pharmaceuticals, Inc., a pharmaceutical company, from 2012 to 2015, and Humanigen, Inc., a pharmaceutical company, from 2012 to 2013. Dr. Henner received a Ph.D. in Microbiology from the University of Virginia and did postgraduate training at the Scripps Clinic and Research Foundation.
How old is Dennis Henner?
Dennis Henner is 67, he’s been the Independent Director of Forty Seven since 2015. There are 1 older and 8 younger executives at Forty Seven. The oldest executive at Forty Seven, Inc. is Irving Weissman, 78, who is the Independent Director.
What’s Dennis Henner’s mailing address?
Dennis’s mailing address filed with the SEC is C/O MPM ASSET MANAGEMENT, 111 HUNTINGTON AVENUE, 31ST FLOOR, BOSTON, MA, 02199.
Insider trading at Forty Seven
Over the last few years, insiders at Forty Seven have traded over $4,118,522 worth of Forty Seven stock and bought 2,621,245 units worth $41,666,515 . The most active insider traders include Tench Coxe, Michael L Speiser, and Jeffrey W Bird. On average, Forty Seven executives and independent directors trade stock every 7 days with the average trade being worth of $569,591. The most recent stock trade was executed by Mark Anthony Mc Camish on 20 May 2019, trading 16,500 units of FTSV stock currently worth $80,520.
What does Forty Seven do?
Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA.
What does Forty Seven’s logo look like?
Complete history of Dennis Henner stock trades at Rigel Pharmaceuticals and Forty Seven
Forty Seven executives and stock owners
Forty Seven executives and other stock owners filed with the SEC include:
- Mark McCamish, President, Chief Executive Officer, Director
- Ann Rhoads, Chief Financial Officer
- Chris Takimoto, Chief Medical Officer
- Ian Clark, Independent Director
- Craig Gibbs, Chief Business Officer
- Kristine Ball, Independent Director
- Jeffrey Bird, Lead Independent Director
- Dennis Henner, Independent Director
- Ravindra Majeti, Independent Director
- Irving Weissman, Independent Director
- Samuel J Iii Pullara,
- Harbor Master Investors (Ca…, 10% owner
- Michael L Speiser, 10% owner
- Stefan A Dyckerhoff,
- Venture Partners X, L.P.Lig…,
- Hill Ventures Sutter,
- Peter Nieh, 10% owner
- Christopher J Schaepe, Director
- Tench Coxe, 10% owner
- Dennis Henner, Director
- James N White, 10% owner
- Venture Partners Select Ii,…,
- Ravi Mhatre, 10% owner